141 related articles for article (PubMed ID: 21247815)
1. [Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma].
Reverter JL; Colomé E
Endocrinol Nutr; 2011 Feb; 58(2):75-83. PubMed ID: 21247815
[TBL] [Abstract][Full Text] [Related]
2. [Clinical endocrinologists' perception of the deleterious effects of TSH suppressive therapy in patients with differentiated thyroid carcinoma].
Reverter JL; Colomé E; Puig Domingo M; Julián T; Halperin I; Sanmartí A
Endocrinol Nutr; 2010 Oct; 57(8):350-6. PubMed ID: 20494634
[TBL] [Abstract][Full Text] [Related]
3. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
4. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
[TBL] [Abstract][Full Text] [Related]
6. Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
Do Cao C; Wémeau JL
Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S47-52. PubMed ID: 26826483
[TBL] [Abstract][Full Text] [Related]
7. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
[TBL] [Abstract][Full Text] [Related]
8. Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma.
Olveira G; Almaraz MC; Soriguer F; Garriga MJ; Gonzalez-Romero S; Tinahones F; Ruiz de Adana MS
Clin Endocrinol (Oxf); 1997 Jun; 46(6):707-11. PubMed ID: 9274701
[TBL] [Abstract][Full Text] [Related]
9. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.
Santoro AB; Vargens DD; Barros Filho Mde C; Bulzico DA; Kowalski LP; Meirelles RM; Paula DP; Neves RR; Pessoa CN; Struchine CJ; Suarez-Kurtz G
Br J Clin Pharmacol; 2014 Nov; 78(5):1067-75. PubMed ID: 24910925
[TBL] [Abstract][Full Text] [Related]
10. Thyroid Hormone Suppression Therapy.
Biondi B; Cooper DS
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):227-237. PubMed ID: 30717904
[TBL] [Abstract][Full Text] [Related]
11. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
Francia G; Davì MV; Petroziello A; Sussi PL
Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
[TBL] [Abstract][Full Text] [Related]
12. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer.
Altuntaş SÇ; Hocaoğlu Ç
Horm Metab Res; 2021 Oct; 53(10):683-691. PubMed ID: 34607367
[TBL] [Abstract][Full Text] [Related]
13. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
14. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma.
Botella-Carretero JI; Gómez-Bueno M; Barrios V; Caballero C; García-Robles R; Sancho J; Escobar-Morreale HF
Endocr Relat Cancer; 2004 Jun; 11(2):345-56. PubMed ID: 15163309
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
Denizot A; Delfino C; Dutour-Meyer A; Fina F; Ouafik L
Thyroid; 2003 Sep; 13(9):867-72. PubMed ID: 14588101
[TBL] [Abstract][Full Text] [Related]
16. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
Sugitani I; Fujimoto Y
Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
[TBL] [Abstract][Full Text] [Related]
17. Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.
Fussey JM; Khan H; Ahsan F; Prashant R; Pettit L
Head Neck; 2017 Dec; 39(12):2567-2572. PubMed ID: 28960722
[TBL] [Abstract][Full Text] [Related]
18. [Increase in TSH levels in thyroid carcinoma patients after withdrawal of suppressive levothyroxine medication].
Hackländer S; Voth E; Schicha H
Nuklearmedizin; 1996 Oct; 35(5):170-4. PubMed ID: 9005413
[TBL] [Abstract][Full Text] [Related]
19. Highly sensitive determination of TSH in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.
Mann K; Saller B; Mehl U; Hörmann R; Moser E
Nuklearmedizin; 1988 Feb; 27(1):24-8. PubMed ID: 3368333
[TBL] [Abstract][Full Text] [Related]
20. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
